ArticleCancer medicine2026
The Impact of the G8 Score on Survival Outcomes in Patients With Head and Neck Cancer Undergoing Concurrent Radiotherapy With Cetuximab due to Contraindications With Cisplatin.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePatients unable to receive cisplatin due to age, comorbidities, or reduced performance status are commonly treated with concurrent radiotherapy (RT) and cetuximab. This study evaluated the prognostic significance of the Geriatric 8 (G8) score and the Charlson Comorbidity Index (CCI) in predicting survival outcomes in this population.
methodsWe retrospectively analyzed data from 52 patients with locally advanced or loco-regional recurrent head and neck squamous cell carcinoma (HNSCC) who were treated with RT and cetuximab between 2011 and 2024. Patients with p16-positive oropharyngeal or nasopharyngeal cancers were excluded. Overall survival (OS) and cancer-specific survival (CSS) were assessed according to G8 and CCI scores using ROC analysis, Kaplan-Meier curves, and Cox regression.
resultsThe median follow-up was 50 months. A G8 cut-off of 9.75 was identified (AUC: 0.713, p < 0.01). Patients with G8 ≥ 9.75 showed significantly improved OS (median: 47 vs. 7 months, p < 0.01) and 4-year CSS (66% vs. 32%, p < 0.01). In the definitive treatment group, 4-year CSS was 68% in high-G8 patients vs. 42% in low-G8 patients. In the recurrence group, 4-year CSS was 63% among high-G8 patients, whereas no patient with a low G8 score survived beyond 4 years. Multivariate analysis identified G8 < 9.75 (HR: 4.72, p < 0.01) and RT dose < 60 Gy (HR: 3.01, p = 0.01) as independent predictors of poor OS. No significant association was observed between CCI and survival.
conclusionThe G8 score is a valuable prognostic tool for cisplatin-ineligible HNSCC patients treated with RT and cetuximab. Low G8 scores were strongly associated with worse outcomes, highlighting the need for alternative therapeutic strategies in this high-risk subgroup.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.